CardioScale Wins The Combating Terrorism Technology StartUp Challange (CTTSC3) Presented by The US Department of Defence (CTTSO), Israel Department of Defence (MAFAT) and The MIT Enterprise Forum of Israel.
CardioScale Ltd. announces that the application for its proprietary CVRI Index has been approved by the Australian Authority IP Australia, this announcement comes following the approval of similar patents in the US, China and Japan
CardioScale Ltd. Announces that its proprietary CVRI Index has been approved by both the Chinese and Japanese Patent Authorities, giving CardioScale Ltd. a meaningful foothold in Asian markets.
CardioScale announced today that its Patent in Mainland China had successfully passed examination and was fully granted. The company specializing in early detection of hemodynamic deterioration based on its innovative technology announced that the Patent Office of chin...
The company specializing in early detection of hemodynamic deterioration based on its innovative technology announced today that the U.S. Patent and Trademark Office has granted its Reserve Index patent
Innovation in Emergency Medicine, Preparedness, Management & Rehabilitation.
Paris – France | 24 – 25 April, 2017
Sharing the best practices and technologies in the field of Medical Emergency, Medical Device & HealthCare IT companies in the various fields of emergency me...
Taiwan is a country with advanced medical technology, high-efficient infrastructure, and potential aging markets nearby. In 2016 Scientific AmericanWorldview: A Global Biotechnology Perspective, Taiwan’s business friendly environment, biotechnology venture capital avai...
We are delighted to inform that CardioScale's abstract has been selected by the Congress Scientific Committee to present its studies: "The cardiovascular reserve index (CVRI) - a potential indicator of hemodynamic deterioration" at the Vienna Congress for intensive ca...
